caladrius biosciences developing next generation cell therapies about caladrius caladrius biosciences inc is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications the company is investigating its lead product candidate clbs an ex vivo expanded polyclonal t regulatory cell therapy for the treatment of recentonset type  diabetes in a currently enrolling phase  trial newsjuly  caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetesjune  caladrius biosciences joins russell microcap® indexjune  invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapieseventsjune  th international symposium on stem cell therapy  cardiovascular innovationsjune  th annual ld micro invitationalmay   first quarter financial results sign up to our email list to receive caladrius announcements email address this iframe contains the logic required to handle ajax powered gravity forms technologies  capabilitiest regulatory cell technology cd cell technology our company  caladrius our company our companycaladrius biosciences inc is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications the company is investigating its lead product candidate clbs an ex vivo expanded polyclonal t regulatory cell therapy for the treatment of recentonset type  diabetes in a currently enrolling phase  trialthrough developing and manufacturing cell therapies to treat those in need we are dedicated to enabling people to enjoy a healthier span of life our overall vision includes commitment to the followingwe will be recognized for our culture of respect our teamwork and our patient and customercentric mindsetwe will drive the evolution of the cell therapy industrywe will generate industryleading growth through our significant operational scale our innovation and our executional excellencewe will set ourselves apart in the industry creating value by allowing our people shareholders and company to prosperwe will bring significant lifeimproving medical treatments to patientsmissionat caladrius biosciences our mission is to bring new innovative and treatment paradigmchanging medical therapies to market based on our unique expertise and experience and in so doing to improve patients’ lives and create value for our shareholdersresearch and discoveryto accomplish our mission and see our vision through to the end we are combining stateoftheart science with the body’s intricate biologic systems and are working to leverage our bodies’ development of cell capabilities with complex and specific functions we believe that each study we perform expands the foundations of cell therapy and biologic science and believe that our research and discovery will have meaningful and lasting influence we pledge to use our experience and knowledge to advance science research and development patientswe conduct all of our work in order to ultimately benefit the patients who put their trust and hope in our hands we will continue to pursue therapies in areas of significant unmet medical need so that we can have the greatest impact on them we know it won’t be easy but we are committed to striving to successfully guide our product candidates through the development process in order that they may ultimately reach and serve the patientseducation the cell therapy industry needs credible sources disseminating information we pledge to be that credible source promoting ethical science and ethical business and playing an educational role in bringing cell therapy to the public which includes dispelling controversy decreasing confusion and increasing awareness of cellular therapies and their potential to heal the body and fight disease overview  caladrius overview caladrius biosciences is developing cellular therapeutics to treat certain diseases we leverage our internal specialized cell therapy clinical development expertise to select and develop earlystage cell therapy candidates with the intention of partnering these candidates post proofofconcept in humansclbsour current lead product candidate clbs is an autologous ex vivo polyclonal t regulatory cell treg clinical phase  therapy targeting adolescents with recentonset type  diabetes mellitus “td” this program is based on the use of tregs to treat diseases caused by imbalances in an individuals immune system this novel approach seeks to restore immune balance by enhancing treg number and functionclbsour cd cell technology has led to the development of therapeutic candidates designed to address diseases and conditions caused by ischemia ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted through the administration of cd cells we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area our clinical trial notification for a pivotal phase  trial investigating clbs a candidate for cli was submitted to the japanese pharmaceutical and medical device agency pmda and was cleared to proceed management team  caladrius management team david j mazzo phd president chief executive officer and director biodavid j mazzo was appointed as caladrius chief executive officer and as a member of our board on january   in addition dr mazzo was appointed as president of the company in march  dr mazzo brings to the company over  years of experience in the pharmaceutical industry prior to joining caladrius dr mazzo served from august  to october  as chief executive officer and as a member of the board of directors of regado biosciences inc a nasdaqlisted biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and subacute cardiovascular indications prior to his leading regado from march  to april  dr mazzo was president chief executive officer and a director of æterna zentaris inc a publicly held international biopharmaceutical company from  until  dr mazzo served as president chief executive officer and a director of chugai pharma usa llc a biopharmaceutical company which was the us subsidiary of chugai pharmaceutical co ltd of japan dr mazzo has also held senior management and executive positions in research and development and was a director of the essex chimie european subsidiary at scheringplough corporation a publicly held pharmaceutical company that was subsequently acquired by merck  co inc hoechst marion roussel inc the us subsidiary of hoechst ag which was subsequently acquired by sanofi a multinational pharmaceuticals company and rhonepoulenc rorer inc a subsidiary of rhonepoulene sa a french pharmaceuticals company which was subsequently acquired by hoechst ag he also previously served on the board of avanir pharmaceuticals inc a biotechnology company which was sold to otsuka holdings in  he currently serves on the board of directors of psivida corp a publicly held biopharmaceutical company in the role of nonexecutive chairman dr mazzo earned a ba in the honors program interdisciplinary humanities and a bs in chemistry from villanova university in addition dr mazzo received his ms in chemistry and his phd degree in analytical chemistry from the university of massachusetts amherst he was also a research fellow at the ecole polytechnique federale de lausanne switzerland joseph talamo senior vice president and chief financial officer biojoseph talamo was promoted to senior vice president and chief financial officer in october  from his previous role when he joined caladrius in  as the corporate controller and chief accounting officer he is a versatile finance executive with leadership experience in publiclytraded development and commercialstage companies along with a strong background in sec compliance he has led companywide forecasting planning and analysis activities including for ma and has had extensive experience with integrating transactions and raising capital at caladrius mr talamo has been responsible for numerous financial functions including sec reporting forecasting planning and analysis cash management and accounting prior to joining caladrius from  to  mr talamo held various senior positions at osi pharmaceuticals inc “osi” a publiclytraded biopharmaceutical company focused on discovering developing and commercializing products for the treatment of cancer diabetes and obesity and most recently served as its vice president and corporate controller from  to  and its corporate controller from  to  while at osi mr talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of tarceva® osis targeted therapy approved for the treatment of patients with nonsmall cell lung cancer and pancreatic cancer prior to osi mr talamo worked at bristolmyers squibb from  to  in the financial reporting and consolidations group and at kpmg from  to  in the health care and life sciences audit group mr talamo has served as treasurer of the stem for life foundation a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise since  mr talamo also served as treasurer of the osi pharmaceuticals foundation from  to  mr talamo received a bba in accounting from hofstra university in  and an mba in finance from hofstra university in  mr talamo is a certified public accountant in the state of new york douglas w losordo md facc faha senior vice president clinical medical and regulatory affairs and chief medical officer bio dr losordo was appointed chief medical officer of the company effective august   dr losordo served from  to  as a member of the scientific advisory board of caladrius prior to his appointment as the company’s chief medical officer dr losordo served as vice president new therapies development regenerative medicine and baxter ventures at baxter international from october  through february  he is an adjunct professor of medicine at northwestern university in chicago illinois from  through  dr losordo was the director of the feinberg cardiovascular research institute and the eileen m foell professor of heart research at northwestern university’s school of medicine and director of the program in cardiovascular regenerative medicine at northwestern memorial hospital from  through  he was a professor of medicine at tufts university school of medicine and chief of cardiovascular research at st elizabeth’s medical center in boston he is boardcertified in internal medicine cardiovascular disease and interventional cardiology dr losordo’s major research interests encompass angiogenesisvasculogenesis progenitoradult stem cells tissue repairregeneration and vascular biology he received his md from the university of vermont dr losordo has engaged in careerlong efforts to develop novel therapeutics and as a scientist he obtained over  million in national institutes of health funding for discovering and developing new therapeutic concepts in the laboratory providing the basis for clinical studies he has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases including therapies now in phase  testing he is a highly sought after speaker having given over  international lectures he has served as an associate editor of circulation research the basic science journal of the american heart association and serves on the editorial boards of a number of scientific journals since  he has served on the scientific advisory board of the stem for life foundation a public charity devoted to accelerating development of cell therapies todd girolamo jd general counsel and corporate secretary biotodd girolamo joined caladrius in  he is a seasoned attorney specializing in healthrelated products and businesses as a member of the caladrius senior management team mr girolamo has been responsible for managing all legal aspects of the company’s research and development pipeline from preclinical research to multinational pivotal clinical trials including academic and corporate collaborations he has been responsible for the company’s licensing activities the strategy maintenance and prosecution of the company’s extensive global patent estate and the management of all litigation involving the company and its subsidiaries mr girolamo began his legal career as an associate at cahill gordon  reindel and he concluded his tenure in private practice at reid  priest where he gained expertise as a general commercial litigator practicing in the areas of intellectual property securities law employment law and bankruptcy in addition to over a decade of experience as both corporate counsel and private practitioner mr girolamo spent  years on wall street where he specialized in therapeutic healthcare equity securities at oppenheimer  co cibc world markets leerink swann  company and summer street research partners mr girolamo received a bachelor of arts from harvard college juris doctor from the university of pennsylvania law school and master of business administration from columbia business school raj prabhakar senior vice president business development biosince  raj prabhakar has served as head of business development and reports directly to ceo dr david mazzo raj leads all outlicensing inlicensing ma and partnership opportunities and serves on the executive committee of caladrius biosciences current priorities include global partnerships for each of the investigational clinical candidates in immuneoncology immunemodulation and cardiovascular indications in addition to manufacturing jvs and acquisitions prior to caladrius biosciences raj prabhakar served as vice president and head of business development for celsion corporation from  to  including the acquisition of egen inc a gene therapy and delivery company at celsionegen he led partnerships for immuneoncology gene therapy small molecules new formulations and oligonucleotide delivery for dna rna and gene editing candidates raj has particular transaction experience in asiapacific with leading pharmaceutical companies in japan and china prior to celsion raj was employed at path global vaccine development group protiveris osiris therapeutics and harvard medical schoolbrigham  women’s hospital in multiple corporate development business development commercialization and research roles raj holds an mba from the harvard business school and dual bachelors of science degrees in biology and mechanical engineering from the massachusetts institute of technology david schloss vice president human resources biodavid schloss a senior human resources executive and former attorney with over  years of leadership experience joined caladrius biosciences in  as vice president human resources at the company mr schloss is responsible for the development and delivery of compensation benefits organizational design and development recruitment and employee relations mr schloss comes to caladrius formerly neostem with a strong resume of experience in the pharmaceutical and biotechnology industries prior to joining caladrius he served as svp human resources with plus diagnostics acquired by miraca life sciences prior to plus diagnostics mr schloss led human resources for orapharma from   a private equity owned specialty pharmaceutical company focused on oral health care mr schloss helped grow the company and was instrumental in its acquisition and integration by valeant pharmaceuticals international prior to orapharma from  mr schloss was vice president human resources for eurand pharmaceuticals a publicly traded specialty pharmaceutical company based in italy that develops manufactures and commercializes pharmaceutical and biopharmaceutical products while with eurand mr schloss helped build the commercial organization that launched zenpep® for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis eurand was acquired by aptalis in  from  mr schloss led human resources for imclone systems a fully integrated global biopharmaceutical company engaged in the development and commercialization of a portfolio of targeted biological oncology treatments he also led imclone system’s human resources through its acquisition by eli lilly in  additionally mr schloss spent  years with glaxosmithkline in a number of senior level hr roles across the us and internationally before beginning his career in human resources mr schloss was an attorney practicing in the representation of management in all phases of labor relations and employment law he earned a ba from clark university and a jd from the university of miami school of law he currently serves on the pennsylvania advisory board of the devereux foundation a leading nonprofit behavioral health organization that provides support and services to children and adults with intellectual emotional developmental and behavioral challenges greg berkin vice president information technology bioms computer sciencecomputer forensics fairleigh dickinson university greg berkin joined caladrius in january  since that time greg has been responsible for transforming external it support into an internal team working as a highly efficient operating unit across all five caladrius and pct sites he also manages all groups within it networking pc applications business solutions and telecom before joining caladrius greg held director and management roles in it at companies including regado biosciences aeterna zentaris and chugai pharma usa greg has more than  years in the technical profession with  years of unparalleled managerial experience specializing in production systems network engineering facility operations project management hybrid cloudcomputing and cybersecurity news  events  caladrius news  events press releases caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes july   basking ridge nj july   – caladrius biosciences inc nasdaq clbs “caladrius” or the “company” a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications announces that  of subjects have been treated in the sanford project trex study a prospective randomized placebocontrolled doubleblind phase  clinical trial to evaluate the safety and efficacy of the company’s clbs as a treatment for recentonset type  diabetes td read more caladrius biosciences joins russell microcap® index june   basking ridge nj june   — caladrius biosciences inc nasdaqclbs “caladrius” or the “company” a cellular therapeutics development company with a pipeline focused on autoimmune disease and select cardiovascular indications announces today that the company has joined the russell microcap index as part of the russell indexes annual reconstitution effective after the us financial market opens today read more invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies june   san diego ca and basking ridge nj june   – invetech a global leader in instrument development custom automation and contract manufacturing in collaboration with caladrius biosciences nasdaq clbs a cell therapy company with a select therapeutic development pipeline focused on immune modulation today announced that they have been jointly named recipients of a  good design award® the counterflow centrifuge device cfc was selected as best in category for medical and scientific product design read more view all press releases media coverage in the clinic caladrius biosciences july   bioworld highlights caladrius’ sanford project trex study and upcoming milestones read more type  diabetes cell therapy study shows promise in pediatrics july   md magazine discusses clbs halfway through enrollment in the sanford project trex study with kurt grifin md phd director of clinical trials for the sanford project read more practical cure project update caladrius biosciences inc treg april   juvenile diabetes cure alliance details previous clbs study results and how the t regulatory cell technology works read more view all media coverage events th international symposium on stem cell therapy  cardiovascular innovations jun   th international symposium on stem cell therapy  cardiovascular innovations venue hospital general universitario gregorio maranon madrid spain website httpcardiovascularcelltherapycomwpcontentuploadspreliminaryagendajuneversionreducidapdf read more httpcardiovascularcelltherapycomwpcontentuploadspreliminaryagendajuneversionreducidapdf th annual ld micro invitational jun   am pt date and time tuesday june    am pt venue luxe sunset hotel los angeles california website httpswwwldmicrocomevents presentation company presentation speaker david j mazzo chief executive officer caladrius webcast httpwswcomwebcastldmicroclbs read more httpwswcomwebcastldmicroclbs  first quarter financial results may  pm et caladrius’ management will host a conference call on may   beginning at  pm eastern time to review  first quarter financial results provide a company update and answer questions stockholders and other interested parties may participate in the conference call by dialing  us or  international and providing conference id  the call will also be broadcast live on the internet via the company’s website at wwwcaladriuscomevents the webcast will be archived on the company’s website for  days read more view all events contact us  caladrius contact us get in touchuse the form below to send us a message what type of inquiry is this please select investor inquirymedia inquiryclinical trial inquirycareer inquirygeneralother inquiryname first last email phonelocation city afghanistanalbaniaalgeriaamerican samoaandorraangolaantigua and barbudaargentinaarmeniaaustraliaaustriaazerbaijanbahamasbahrainbangladeshbarbadosbelarusbelgiumbelizebeninbermudabhutanboliviabosnia and herzegovinabotswanabrazilbruneibulgariaburkina fasoburundicambodiacamerooncanadacape verdecayman islandscentral african republicchadchilechinacolombiacomoroscongo democratic republic of thecongo republic of thecosta ricacôte divoirecroatiacubacuraçaocyprusczech republicdenmarkdjiboutidominicadominican republiceast timorecuadoregyptel salvadorequatorial guineaeritreaestoniaethiopiafaroe islandsfijifinlandfrancefrench polynesiagabongambiageorgiagermanyghanagreecegreenlandgrenadaguamguatemalaguineaguineabissauguyanahaitihondurashong konghungaryicelandindiaindonesiairaniraqirelandisraelitalyjamaicajapanjordankazakhstankenyakiribatinorth koreasouth koreakosovokuwaitkyrgyzstanlaoslatvialebanonlesotholiberialibyaliechtensteinlithuanialuxembourgmacedoniamadagascarmalawimalaysiamaldivesmalimaltamarshall islandsmauritaniamauritiusmexicomicronesiamoldovamonacomongoliamontenegromoroccomozambiquemyanmarnamibianaurunepalnetherlandsnew zealandnicaraguanigernigerianorthern mariana islandsnorwayomanpakistanpalaupalestine state ofpanamapapua new guineaparaguayperuphilippinespolandportugalpuerto ricoqatarromaniarussiarwandasaint kitts and nevissaint luciasaint vincent and the grenadinessamoasan marinosao tome and principesaudi arabiasenegalserbiaseychellessierra leonesingaporesint maartenslovakiasloveniasolomon islandssomaliasouth africaspainsri lankasudansudan southsurinameswazilandswedenswitzerlandsyriataiwantajikistantanzaniathailandtogotongatrinidad and tobagotunisiaturkeyturkmenistantuvaluugandaukraineunited arab emiratesunited kingdomunited statesuruguayuzbekistanvanuatuvatican cityvenezuelavietnamvirgin islands britishvirgin islands usyemenzambiazimbabwe country comments caladrius biosciences hq allen road nd floor basking ridge nj  tel caladrius biosciences new york lexington avenue suite  new york ny  tel  sign up to our email list to receive caladrius announcements email address this iframe contains the logic required to handle ajax powered gravity forms sec filings  caladrius sec filings caladrius biosciences inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report caladrius biosciences inc  product pipeline review   published by global markets direct product code  published july   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license caladrius biosciences inc  product pipeline review   published july   content info  pages description summary global markets directs caladrius biosciences inc  product pipeline review   provides an overview of the caladrius biosciences incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by caladrius biosciences inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of caladrius biosciences inc the report provides overview of caladrius biosciences inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses caladrius biosciences incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features caladrius biosciences incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate caladrius biosciences incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for caladrius biosciences inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding caladrius biosciences incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures caladrius biosciences inc snapshot caladrius biosciences inc overview key information key facts caladrius biosciences inc  research and development overview key therapeutic areas caladrius biosciences inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities caladrius biosciences inc  pipeline products glance caladrius biosciences inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities caladrius biosciences inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities caladrius biosciences inc  drug profiles clbs product description mechanism of action rd progress clbs product description mechanism of action rd progress stem cell therapy for amd and retinitis pigmentosa product description mechanism of action rd progress caladrius biosciences inc  pipeline analysis caladrius biosciences inc  pipeline products by route of administration caladrius biosciences inc  pipeline products by molecule type caladrius biosciences inc  recent pipeline updates caladrius biosciences inc  dormant projects caladrius biosciences inc  discontinued pipeline products discontinued pipeline product profiles clbs caladrius biosciences inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables caladrius biosciences inc  key information caladrius biosciences inc  key facts caladrius biosciences inc  pipeline by indication  caladrius biosciences inc  pipeline by stage of development  caladrius biosciences inc  monotherapy products in pipeline  caladrius biosciences inc  partnered products in pipeline  caladrius biosciences inc  partnered products combination treatment modalities  caladrius biosciences inc  phase ii  caladrius biosciences inc  phase i  caladrius biosciences inc  preclinical  caladrius biosciences inc  discovery  caladrius biosciences inc  pipeline by route of administration  caladrius biosciences inc  pipeline by molecule type  caladrius biosciences inc  recent pipeline updates  caladrius biosciences inc  dormant developmental projects caladrius biosciences inc  discontinued pipeline products  caladrius biosciences inc  other locations caladrius biosciences inc  subsidiaries list of figures caladrius biosciences inc  pipeline by indication  caladrius biosciences inc  pipeline by stage of development  caladrius biosciences inc  monotherapy products in pipeline  caladrius biosciences inc  pipeline by route of administration  caladrius biosciences inc  pipeline by molecule type  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved clbs stock price  caladrius biosciences inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern p updated all the companies in jeff bezos’s empire in one large chart p scaramucci provides a shocking bannon comparison that defies anatomy p updated bitcoin investors things may get very ugly soon if this chart overlay is right p baidu adrs rally  after earnings beat p breaking senators demand house conference promise before voting on skinny obamacare repeal p jonathan golub leaves rbc to head equities strategy at credit suisse report p amazon earnings forecast shows spending expected to continue p a quarter of sp ’s  climb due to five stocks yes those five p nuvasive shares drop after announced coo cfo departures p boston beer jumps on stellar secondquarter earnings to be replaced home investing quotes stocks united states clbs overview compare quotes stock screener earnings calendar sectors nasdaq clbs us nasdaq join td ameritrade find a broker caladrius biosciences inc watchlist createclbsalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones three healthcare deals today are paying huge premiums mar   at  am et by philip van doorn investors in healthcare stocks get rich as ma booms mar   at  am et by philip van doorn biotech startups’ cellbased diabetes attack creating cells that help the body beat the condition could free patients from insulin therapy or resorting to pancreas transplants jun   at  pm et on the wall street journal cfo moves caladrius biosciences selectica oct   at  pm et on the wall street journal stocks to watch forest oil discovery labs xyratex oct   at  am et on the wall street journal cfo moves us steel tetralogic pharmaceuticals neostem aug   at  pm et on the wall street journal recent news other news press releases  new developments give hope for type i diabetes sufferers  new developments give hope for type i diabetes sufferers jul   at  pm et on seeking alpha biotech startups’ cellbased diabetes attack creating cells that help the body beat the condition could free patients from insulin therapy or resorting to pancreas transplants jun   at  pm et on the wall street journal caladrius biosciences clbs presents at th annual ld micro invitational conference  slideshow caladrius biosciences clbs presents at th annual ld micro invitational conference  slideshow jun   at  pm et on seeking alpha caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript may   at  pm et on seeking alpha q caladrius biosciences inc q caladrius biosciences inc may   at  pm et on edgar online  edg  q k the strange case of caladrius biosciences apr   at  am et on seeking alpha company news for march   mar   at  am et on zackscom caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript mar   at  pm et on seeking alpha caladrius biosciences up nearly  after asset sale mar   at  am et on seeking alpha k caladrius biosciences inc mar   at  am et on edgar online  edg  q k caladrius biosciences clbs presents at th annual roth conference mar   at  pm et on seeking alpha is caladrius biosciences inc a buy mar   at  pm et on seeking alpha while big diabetes stagnates smaller companies are moving faster than ever feb   at  pm et on gurufocuscom why i liquidated most of my biotech holdings jan   at  am et on seeking alpha biggest movers in services stocks now – ccih pmd gen zdge jan   at  pm et on investorplacecom biggest movers in services stocks now – mbly bcor inxn shop dec   at  am et on investorplacecom biggest movers in services stocks now – ehic wtw hlth fncx dec   at  am et on investorplacecom hottest services stocks now – ehic exas cyh dwch dec   at  pm et on investorplacecom hottest services stocks now – inod matr bita avid dec   at  am et on investorplacecom biggest movers in services stocks now – bkd ltrpa iiji knd dec   at  am et on investorplacecom caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes jul   at  am et on globenewswire tcell immunotherapy market nd edition  tcell immunotherapy market nd edition  jul   at  pm et on pr newswire  prf caladrius biosciences joins russell microcapr index caladrius biosciences joins russell microcapr index jun   at  am et on globenewswire invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies jun   at  am et on pr newswire  prf caladrius biosciences to participate at upcoming june conferences caladrius biosciences to participate at upcoming june conferences jun   at  am et on globenewswire caladrius biosciences closes the sale of its remaining interest in pct to hitachi chemical for  million caladrius biosciences closes the sale of its remaining interest in pct to hitachi chemical for  million may   at  pm et on globenewswire caladrius biosciences announces  first quarter financial results caladrius biosciences announces  first quarter financial results may   at  pm et on globenewswire caladrius biosciences to host  first quarter financial results conference call on may   at  pm eastern time caladrius biosciences to host  first quarter financial results conference call on may   at  pm eastern time may   at  am et on globenewswire caladrius biosciences to participate at upcoming may conferences caladrius biosciences to participate at upcoming may conferences may   at  am et on globenewswire shareholder alert monteverde  associates pc announces an investigation of caladrius biosciences inc  clbs apr   at  pm et on pr newswire  prf caladrius biosciences to hold  annual stockholder meeting on may  apr   at  pm et on globenewswire caladrius biosciences to participate at upcoming april conferences apr   at  am et on globenewswire caladrius biosciences announces addition of four clinical sites including joslin diabetes center for the ongoing phase  study of clbs in td apr   at  am et on globenewswire caladrius biosciences announces  fourth quarter and full year financial results mar   at  am et on globenewswire hitachi chemical signs agreement to purchase from caladrius biosciences the remaining  interest in pct for  million mar   at  pm et on globenewswire caladrius biosciences to host  fourth quarter and full year financial results conference call on march   at  am eastern time mar   at  am et on globenewswire caladrius biosciences to present at upcoming march conferences mar   at  am et on globenewswire caladrius biosciences awarded  million grant from cirm in support of phase  clinical trial of clbs to treat type  diabetes feb   at  pm et on globenewswire caladrius biosciences to present at upcoming february conferences feb   at  am et on globenewswire caladrius biosciences announces addition of three clinical sites including university of california san francisco for the ongoing phase  study of clbs in td jan   at  am et on globenewswire caladrius biosciences inc caladrius biosciences inc operates as a global healthcare company which engages in developing cellular therapies that repair damaged tissue cells and organs and restore their normal function it is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent treat or cure disease its business includes the development of novel proprietary cell therapy products as well as a revenuegenerating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products the company was founded in september  and is headquartered in new york ny see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations aug   at  am et on benzingacom hc wainwright upgrades caladrius biosciences to buy sets  price target apr   at  am et on benzingacom competitors name chg  market cap repligen corp  b athersys inc  m pluristem therapeutics inc  m cryocell international inc  m cellular biomedicine group inc  m competitor data provided by partner content trending tickers powered by amzn  intc  sbux  fslr  twtr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pscaramucci provides a shocking bannon comparison that defies anatomy pbitcoin investors things may get very ugly soon if this chart overlay is right pbaidu adrs rally  after earnings beat pbreakingsenators demand house conference promise before voting on skinny obamacare repeal pjonathan golub leaves rbc to head equities strategy at credit suisse report pamazon earnings forecast shows spending expected to continue pa quarter of sp ’s  climb due to five stocks yes those five pnuvasive shares drop after announced coo cfo departures pboston beer jumps on stellar secondquarter earnings pdow ends at record but tech slump weighs on sp  nasdaq pamazon earnings fall  shares drop pelectronic arts shares fall after firstquarter results prevolution investing and the halftrilliondollar club pfirst solar shares jump  on big earnings beat strong outlook ptreasury yields rebound on raft of solid economic data and att debt deal pwhy millions are locked out of the american dream and you may not have to take your antibiotics pstarbucks adj earnings above expectations teavana stores to close pdan neil drives vws atlas ptrump today president cites ‘big progress’ on gangs as sessions says he’ll stay in job loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pscaramucci provides a shocking bannon comparison that defies anatomy pbitcoin investors things may get very ugly soon if this chart overlay is right pbaidu adrs rally  after earnings beat pbreakingsenators demand house conference promise before voting on skinny obamacare repeal pjonathan golub leaves rbc to head equities strategy at credit suisse report pamazon earnings forecast shows spending expected to continue pa quarter of sp ’s  climb due to five stocks yes those five pnuvasive shares drop after announced coo cfo departures pboston beer jumps on stellar secondquarter earnings pdow ends at record but tech slump weighs on sp  nasdaq pamazon earnings fall  shares drop pelectronic arts shares fall after firstquarter results prevolution investing and the halftrilliondollar club pfirst solar shares jump  on big earnings beat strong outlook ptreasury yields rebound on raft of solid economic data and att debt deal pwhy millions are locked out of the american dream and you may not have to take your antibiotics pstarbucks adj earnings above expectations teavana stores to close pdan neil drives vws atlas ptrump today president cites ‘big progress’ on gangs as sessions says he’ll stay in job loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets after hours market snapshot winners and losers stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pscaramucci provides a shocking bannon comparison that defies anatomy pbitcoin investors things may get very ugly soon if this chart overlay is right pbaidu adrs rally  after earnings beat pbreakingsenators demand house conference promise before voting on skinny obamacare repeal pjonathan golub leaves rbc to head equities strategy at credit suisse report pamazon earnings forecast shows spending expected to continue pa quarter of sp ’s  climb due to five stocks yes those five pnuvasive shares drop after announced coo cfo departures pboston beer jumps on stellar secondquarter earnings pdow ends at record but tech slump weighs on sp  nasdaq pamazon earnings fall  shares drop pelectronic arts shares fall after firstquarter results prevolution investing and the halftrilliondollar club pfirst solar shares jump  on big earnings beat strong outlook ptreasury yields rebound on raft of solid economic data and att debt deal pwhy millions are locked out of the american dream and you may not have to take your antibiotics pstarbucks adj earnings above expectations teavana stores to close pdan neil drives vws atlas ptrump today president cites ‘big progress’ on gangs as sessions says he’ll stay in job loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  clbs stock price  caladrius biosciences inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers adp  tsco  vz  orly  ca  jci  ffiv  xl  latest newsall times eastern p updated all the companies in jeff bezos’s empire in one large chart p scaramucci provides a shocking bannon comparison that defies anatomy p updated bitcoin investors things may get very ugly soon if this chart overlay is right p baidu adrs rally  after earnings beat p breaking senators demand house conference promise before voting on skinny obamacare repeal p jonathan golub leaves rbc to head equities strategy at credit suisse report p amazon earnings forecast shows spending expected to continue p a quarter of sp ’s  climb due to five stocks yes those five p nuvasive shares drop after announced coo cfo departures p boston beer jumps on stellar secondquarter earnings to be replaced home investing quotes stocks united states clbs overview compare quotes stock screener earnings calendar sectors nasdaq clbs us nasdaq join td ameritrade find a broker caladrius biosciences inc watchlist createclbsalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest k   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones three healthcare deals today are paying huge premiums mar   at  am et by philip van doorn investors in healthcare stocks get rich as ma booms mar   at  am et by philip van doorn biotech startups’ cellbased diabetes attack creating cells that help the body beat the condition could free patients from insulin therapy or resorting to pancreas transplants jun   at  pm et on the wall street journal cfo moves caladrius biosciences selectica oct   at  pm et on the wall street journal stocks to watch forest oil discovery labs xyratex oct   at  am et on the wall street journal cfo moves us steel tetralogic pharmaceuticals neostem aug   at  pm et on the wall street journal recent news other news press releases  new developments give hope for type i diabetes sufferers  new developments give hope for type i diabetes sufferers jul   at  pm et on seeking alpha biotech startups’ cellbased diabetes attack creating cells that help the body beat the condition could free patients from insulin therapy or resorting to pancreas transplants jun   at  pm et on the wall street journal caladrius biosciences clbs presents at th annual ld micro invitational conference  slideshow caladrius biosciences clbs presents at th annual ld micro invitational conference  slideshow jun   at  pm et on seeking alpha caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript may   at  pm et on seeking alpha q caladrius biosciences inc q caladrius biosciences inc may   at  pm et on edgar online  edg  q k the strange case of caladrius biosciences apr   at  am et on seeking alpha company news for march   mar   at  am et on zackscom caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript mar   at  pm et on seeking alpha caladrius biosciences up nearly  after asset sale mar   at  am et on seeking alpha k caladrius biosciences inc mar   at  am et on edgar online  edg  q k caladrius biosciences clbs presents at th annual roth conference mar   at  pm et on seeking alpha is caladrius biosciences inc a buy mar   at  pm et on seeking alpha while big diabetes stagnates smaller companies are moving faster than ever feb   at  pm et on gurufocuscom why i liquidated most of my biotech holdings jan   at  am et on seeking alpha biggest movers in services stocks now – ccih pmd gen zdge jan   at  pm et on investorplacecom biggest movers in services stocks now – mbly bcor inxn shop dec   at  am et on investorplacecom biggest movers in services stocks now – ehic wtw hlth fncx dec   at  am et on investorplacecom hottest services stocks now – ehic exas cyh dwch dec   at  pm et on investorplacecom hottest services stocks now – inod matr bita avid dec   at  am et on investorplacecom biggest movers in services stocks now – bkd ltrpa iiji knd dec   at  am et on investorplacecom caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes jul   at  am et on globenewswire tcell immunotherapy market nd edition  tcell immunotherapy market nd edition  jul   at  pm et on pr newswire  prf caladrius biosciences joins russell microcapr index caladrius biosciences joins russell microcapr index jun   at  am et on globenewswire invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies jun   at  am et on pr newswire  prf caladrius biosciences to participate at upcoming june conferences caladrius biosciences to participate at upcoming june conferences jun   at  am et on globenewswire caladrius biosciences closes the sale of its remaining interest in pct to hitachi chemical for  million caladrius biosciences closes the sale of its remaining interest in pct to hitachi chemical for  million may   at  pm et on globenewswire caladrius biosciences announces  first quarter financial results caladrius biosciences announces  first quarter financial results may   at  pm et on globenewswire caladrius biosciences to host  first quarter financial results conference call on may   at  pm eastern time caladrius biosciences to host  first quarter financial results conference call on may   at  pm eastern time may   at  am et on globenewswire caladrius biosciences to participate at upcoming may conferences caladrius biosciences to participate at upcoming may conferences may   at  am et on globenewswire shareholder alert monteverde  associates pc announces an investigation of caladrius biosciences inc  clbs apr   at  pm et on pr newswire  prf caladrius biosciences to hold  annual stockholder meeting on may  apr   at  pm et on globenewswire caladrius biosciences to participate at upcoming april conferences apr   at  am et on globenewswire caladrius biosciences announces addition of four clinical sites including joslin diabetes center for the ongoing phase  study of clbs in td apr   at  am et on globenewswire caladrius biosciences announces  fourth quarter and full year financial results mar   at  am et on globenewswire hitachi chemical signs agreement to purchase from caladrius biosciences the remaining  interest in pct for  million mar   at  pm et on globenewswire caladrius biosciences to host  fourth quarter and full year financial results conference call on march   at  am eastern time mar   at  am et on globenewswire caladrius biosciences to present at upcoming march conferences mar   at  am et on globenewswire caladrius biosciences awarded  million grant from cirm in support of phase  clinical trial of clbs to treat type  diabetes feb   at  pm et on globenewswire caladrius biosciences to present at upcoming february conferences feb   at  am et on globenewswire caladrius biosciences announces addition of three clinical sites including university of california san francisco for the ongoing phase  study of clbs in td jan   at  am et on globenewswire caladrius biosciences inc caladrius biosciences inc operates as a global healthcare company which engages in developing cellular therapies that repair damaged tissue cells and organs and restore their normal function it is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent treat or cure disease its business includes the development of novel proprietary cell therapy products as well as a revenuegenerating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products the company was founded in september  and is headquartered in new york ny see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations aug   at  am et on benzingacom hc wainwright upgrades caladrius biosciences to buy sets  price target apr   at  am et on benzingacom competitors name chg  market cap repligen corp  b athersys inc  m pluristem therapeutics inc  m cryocell international inc  m cellular biomedicine group inc  m competitor data provided by partner content trending tickers powered by amzn  intc  sbux  fslr  twtr  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience clbs key statistics  caladrius biosciences inc financial ratios  marketwatch bulletin investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close caladrius biosciences inc nasdaq clbs go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus caladrius biosciences inc market closed  quotes are delayed by  min jul    pm clbs quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description caladrius biosciences inc operates as a global healthcare company which engages in developing cellular therapies that repair damaged tissue cells and organs and restore their normal function it is pursuing the preservation and enhancement of human health globally through the development of cell caladrius biosciences inc operates as a global healthcare company which engages in developing cellular therapies that repair damaged tissue cells and organs and restore their normal function it is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent treat or cure disease its business includes the development of novel proprietary cell therapy products as well as a revenuegenerating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products the company was founded in september  and is headquartered in new york ny valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr david j mazzo   chief executive officer  director mr joseph talamo   chief financial officer  senior vice president dr douglas w losordo   chief medical officer  svpregulatory affairs mr greg berkin   vice presidentinformation technology mr raj prabhakar   senior vice presidentbusiness development insider actions – purchase – sale  – number of transactions  date name shares transaction value  david j mazzo chief executive officer director    derivativenonderivative trans at  per share   robert a preti    derivativenonderivative trans at  per share   douglas w losordo see remarks    derivativenonderivative trans at  per share   joseph talamo svp and cfo    derivativenonderivative trans at  per share   steven s myers director    award at  per share   david j mazzo chief executive officer director    derivativenonderivative trans at  per share   robert a preti    derivativenonderivative trans at  per share   douglas w losordo see remarks    derivativenonderivative trans at  per share   joseph talamo svp and cfo    derivativenonderivative trans at  per share   rimasia capital partners hong kong ltd director    disposition at  per share   rimasia capital partners hong kong ltd director    disposition at  per share   rimasia capital partners hong kong ltd director    disposition at  per share   rimasia capital partners hong kong ltd director    disposition at  per share   rimasia capital partners hong kong ltd director    disposition at  per share   david j mazzo chief executive officer director    derivativenonderivative trans at  per share   robert a preti    derivativenonderivative trans at  per share   douglas w losordo see remarks    derivativenonderivative trans at  per share   joseph talamo svp and cfo    derivativenonderivative trans at  per share   david j mazzo chief executive officer director    derivativenonderivative trans at  per share   robert a preti    derivativenonderivative trans at  per share   douglas w losordo see remarks    derivativenonderivative trans at  per share   joseph talamo svp and cfo    derivativenonderivative trans at  per share   david j mazzo chief executive officer director    award at  per share   steven s myers director    award at  per share   robert a preti    award at  per share   douglas w losordo see remarks    award at  per share   joseph talamo svp and cfo    award at  per share   richard j berman director    award at  per share   steven m klosk director    award at  per share   peter g traber director    award at  per share   greg b brown director    award at  per share   rimasia capital partners hong kong ltd director    disposition at  per share  newslatestcompanyusclbs marketwatch news on clbs three healthcare deals today are paying huge premiums  am march    philip van doorn investors in healthcare stocks get rich as ma booms  am march    philip van doorn newsnonmarketwatchcompanyusclbs other news on clbs  new developments give hope for type i diabetes sufferers  pm july    seeking alpha biotech startups’ cellbased diabetes attack  pm june    the wall street journal interactive edition caladrius biosciences clbs presents at th annual ld micro invitational conference  slideshow  pm june    seeking alpha caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript  pm may    seeking alpha q caladrius biosciences inc  pm may    edgar online  edg  q k the strange case of caladrius biosciences  am april    seeking alpha company news for march    am march    zackscom caladrius biosciences clbs ceo david mazzo on q  results  earnings call transcript  pm march    seeking alpha caladrius biosciences up nearly  after asset sale  am march    seeking alpha k caladrius biosciences inc  am march    edgar online  edg  q k caladrius biosciences clbs presents at th annual roth conference  pm march    seeking alpha is caladrius biosciences inc a buy  pm march    seeking alpha while big diabetes stagnates smaller companies are moving faster than ever  pm feb    gurufocuscom why i liquidated most of my biotech holdings  am jan    seeking alpha biggest movers in services stocks now – ccih pmd gen zdge  pm jan    investorplacecom biggest movers in services stocks now – mbly bcor inxn shop  am dec    investorplacecom biggest movers in services stocks now – ehic wtw hlth fncx  pm dec    investorplacecom hottest services stocks now – ehic exas cyh dwch  pm dec    investorplacecom hottest services stocks now – inod matr bita avid  am dec    investorplacecom biggest movers in services stocks now – bkd ltrpa iiji knd  am dec    investorplacecom loading more headlines at a glance caladrius biosciences inc  allen road th floor basking ridge new jersey  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for clbs newspressreleasecompanyusclbs press releases on clbs caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes  am july    globenewswire tcell immunotherapy market nd edition   pm july    pr newswire  prf caladrius biosciences joins russell microcapr index  am june    globenewswire invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapies  am june    pr newswire  prf caladrius biosciences to participate at upcoming june conferences  am june    globenewswire caladrius biosciences closes the sale of its remaining interest in pct to hitachi chemical for  million  pm may    globenewswire caladrius biosciences announces  first quarter financial results  pm may    globenewswire caladrius biosciences to host  first quarter financial results conference call on may   at  pm eastern time  am may    globenewswire caladrius biosciences to participate at upcoming may conferences  am may    globenewswire shareholder alert monteverde  associates pc announces an investigation of caladrius biosciences inc  clbs  pm april    pr newswire  prf caladrius biosciences to hold  annual stockholder meeting on may   pm april    globenewswire caladrius biosciences to participate at upcoming april conferences  am april    globenewswire caladrius biosciences announces addition of four clinical sites including joslin diabetes center for the ongoing phase  study of clbs in td  am april    globenewswire caladrius biosciences announces  fourth quarter and full year financial results  am march    globenewswire hitachi chemical signs agreement to purchase from caladrius biosciences the remaining  interest in pct for  million  pm march    globenewswire caladrius biosciences to host  fourth quarter and full year financial results conference call on march   at  am eastern time  am march    globenewswire caladrius biosciences to present at upcoming march conferences  am march    globenewswire caladrius biosciences awarded  million grant from cirm in support of phase  clinical trial of clbs to treat type  diabetes  pm feb    globenewswire caladrius biosciences to present at upcoming february conferences  am feb    globenewswire caladrius biosciences announces addition of three clinical sites including university of california san francisco for the ongoing phase  study of clbs in td  am jan    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pall the companies in jeff bezos’s empire in one large chart pscaramucci provides a shocking bannon comparison that defies anatomy pbitcoin investors things may get very ugly soon if this chart overlay is right pbaidu adrs rally  after earnings beat pbreakingsenators demand house conference promise before voting on skinny obamacare repeal pjonathan golub leaves rbc to head equities strategy at credit suisse report pamazon earnings forecast shows spending expected to continue pa quarter of sp ’s  climb due to five stocks yes those five pnuvasive shares drop after announced coo cfo departures pboston beer jumps on stellar secondquarter earnings pdow ends at record but tech slump weighs on sp  nasdaq pamazon earnings fall  shares drop pelectronic arts shares fall after firstquarter results prevolution investing and the halftrilliondollar club pfirst solar shares jump  on big earnings beat strong outlook ptreasury yields rebound on raft of solid economic data and att debt deal pwhy millions are locked out of the american dream and you may not have to take your antibiotics pstarbucks adj earnings above expectations teavana stores to close pdan neil drives vws atlas ptrump today president cites ‘big progress’ on gangs as sessions says he’ll stay in job loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  caladrius biosciences inc clbso company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile caladrius biosciences inc clbso related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse clbso on consolidated issue listed on nasdaq capital market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description caladrius biosciences inc incorporated on october   is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications the companys lead product candidate clbs is a t regulatory cell treg clinical phase ii therapy targeting adolescents with recentonset type  diabetes mellitus tdm using the patients own numerically and functionally enhanced tregs this therapy is based on a platform technology for immunomodulationthe company is focused on commencing the sanford project trex study a phase ii prospective randomized placebocontrolled doubleblind clinical trial to evaluate its treg product candidate clbs in adolescents with recent onset td the company plans to develop its product candidate clbs in japan which is an autologous therapy that derives its cells from peripheral blood through apheresis the companys t regulatory cell technology is applicable to multiple autoimmune and allergic diseases beyond its target indication of tid its other technologies include tumor celldendritic cell technology for immunooncology and cd technology for ischemic repair the company operates over two facilities approximately one in allendale new jersey and over one in mountain view californiathe company competes with lonza group ltd and wuxi apptec » full overview of clbso company address caladrius biosciences inc  allen road fourth floorbasking ridge   nj    p f  company web links home page officers  directors name compensation david mazzo  joseph talamo  douglas losordo  gregory brown  richard berman  » more officers  directors caladrius biosciences inc news briefcaladrius biosciences q loss per share  may   briefcaladrius biosciences q reports loss per share of  mar   roche to start new trial of ac immune drug against alzheimers feb   briefcaladrius biosciences awarded  mln grant from cirm supporting phase  trial of clbs feb   » more clbso news related topics stocksstock screenerhealthcarebiotechnology  medical research ﻿ caladrius biosciences inc product pipeline review    agriculture and animal care agriculture equipment agricultural implements combine harvesters rotavators tillers tractors animal care animal feed animal health pet crop protection agriculture chemical fertilizer net wrap protected cultivation farming field crops fishing fruits and vegetables irrigation plantations seed conventional seed hybrid seed   automotive transportation and warehousing automotive and automotive components auto components automobiles car rental hybrid vehicles lubricant used vehicles general transportation airlines travel aviation railway travel intermediaries logistics and shipping courier packaging transportation value added services warehousing   banking financial services and insurance banking atm banknote online banking retail banking financial services credit rating financial advisory investment banking payments private equity remittance stock broking vending machines wealth management insurance general insurance health insurance life insurance motor insurance reinsurance loans and advances housing loan online loans vehicle loan   consumer products and retail baby care baby apparel and footwear baby equipment baby food baby personal care maternity products consumer electronics audio systems camera computers and peripherals large appliances lighting mobile phone and accessories consumer services ondemand services cosmetics and personal care breath fresheners cosmeceuticals disposable consumer products eye care flavors  fragrance hair care herbal products hygiene nail care oral care personal accessories skin care toiletries home and office furnishings air purifier and freshner bathing furniture gardening home appliances kitchenware mattress stationery water purifier luxury goods artwork products cruises and yachts gems and jewelry luggage and bags watch sporting equipments bicycle golf textile apparel and footwear apparel and footwear apparel and textile athletic apparel innerwear wholesale and retail departmental stores franchisee grocery store cards   defense and security defense aerospace products air force aircraft components army automation and modernization combat vehicles mro services navigational instruments navy security devices access control cyber security fire alarm intrusion alert it security video survelliance weapon ballistic protection military ammunition   education and recruitment education corporate education e learning higher education pre primary primary secondary teacher training test preparation vocational education recruitment   energy and utilities clean technology biofuel carbon fibre hydro solar waste management wind gas lng natural gas shale gas oil drilling and exploration eor equipments and services fuel dispenser midstream naphtha octg oil storage petroleum fuels refining upstream power electricity generation and transmission inverter and ups nuclear power components reservoir development thermal   food beverage and tobacco alcoholic beverages beer cider country liquor imfl wine dairy products butter cheese cream dairy products milk skim milk powder soymilk whey powder whole milk powder yogurt and ice cream food services catering food kiosks quick service restaurant general food confectionary cooking oil dry fruits flour products food ingredients frozen food gluten organic food packaged food processed food ready to eat spice sugar vending machine non alcoholic beverages bottled water carbonated soft drinks energy  sports drink hot beverage iced tea and coffee juice tobacco products cigar cigarette hookah smokeless tobacco   healthcare diagnostics diagnostic lab in vitro diagnostics sleep apnea general healthcare biotechnology healthcare it home healthcare hospitals and clinics old age homes surgery wellness wound care medical devices aesthetic laser biopsy devices bone growth stimulators cardiovascular consumables dental equipment diagnostic imaging ent neurology devices orthopedic pharmaceuticals active pharmaceutical ingredient blood product crams diabetes nutritional and dietary supplements osteoporosis otc drug pharmaceutical pharmacy stores prescribed drug respiratory vaccine   manufacturing and construction construction materials aluminum bricks and blocks cement ceramics electric material explosives glass hardware materials marbles and granite paper refractory materials roofing products sanitaryware steel windows and doors wood industrial engineering industrial automation interior designing infrastructure construction shipbuilding machinery and parts construction machinery elevator and escalator home automation machinery components pipe and valve power tools pump stamping machine tapes other manufacturing activities msme real estate commercial facility management green building hotel real estate consultancy real estate investment trust residential retail   media and entertainment advertising online advertising outdoor advertising films and animation music stores  instruments online music theater video rental gaming and gambling casino online gaming theme park toys video game information services newspaper and magazines intelligence and analytics marketing public publishing relations tourism medical tourism tv radio and broadcasting cable iptv pay tv   metal mining and chemicals chemicals adhesive and sealants coating fine chemicals organic chemicals paint petrochemicals plastics polymer materials rubber specialty chemicals metals  minerals ferrous metals non ferrous metals mining bauxite mining coal mining copper mining gold mining iron ore mining other mining   public sector and administration legal services public services religion funeral wedding   technology and telecom it and ites e commerce embeded systems hosting ict process outsourcing semiconductor software and digital content technology hardware telecommunications and networking cloud services mobile broadband mvas networking and communication equipment smartphone wireless wireline advanced search  call us now     toll free  query  kenresearchcom  login email address password forgot the password  keep me loggedin new here  join us thanks for registering with us please login your your account register  please be patient your registration is in progress it will take few moment name  password  confirm password  phone no  email id    provide corporate academic email id only in case of personal email id provide linkedin profile link in the company address company name    company name and address is required for invoicing process company address    company name and address is required for invoicing process state  country  select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others pin code  validation   if validation code does not match please refresh the page subscribe for the newsletter     forgot password  email id      forgot password  email id      about us services categories news contact us you are here  home  healthcare  pharmaceuticals select a format single user license usd  inr  site license usd  inr  corporate user license usd  inr  alternatively request a quote thanks for submitting the form our marketing team will connect back to you for the budget constraint request a quote name  designation  email  phone no  company name  company url  current budget  security code    if validation code does not match please refresh the page report title  caladrius biosciences incproduct pipeline review quote request for license type license type   license rights price single user license  electronic pdf for single user no print no copy only internal use usd  site license  electronic pdf for site use across authorised users in a single location with print and copy rights only internal use usd  enterprise wide license  electronic pdf for enterprise wide across multiple locations with print and copy rights only internal use usd    request a customized research thanks for letting us know your requirement our research team will connect back to you for the bespoke requirement request a customized research name  designation  email  phone no  company name  company url  current budget  report title  caladrius biosciences incproduct pipeline review requirement  timeline  in working days   security code    if validation code does not match please refresh the page quote request for license type license type   license rights price single user license  electronic pdf for single user no print no copy only internal use usd  site license  electronic pdf for site use across authorised users in a single location with print and copy rights only internal use usd  enterprise wide license  electronic pdf for enterprise wide across multiple locations with print and copy rights only internal use usd    request for sample report thank you for submitting the form the concerned team will will get back to you within next  hours thank you for downloading the sample report request for sample report report title  caladrius biosciences incproduct pipeline review name  designation  email  phone no  company name  company url  security code    if validation code does not match please refresh the page requirement    newsletter by category for regular updates on our latest research reports subscribe newsletter interested areas agriculture and animal care automotive transportation and warehousing banking financial services and insurance consumer products and retail defense and security education and recruitment energy and utilities food beverage and tobacco healthcare manufacturing and construction media and entertainment metal mining and chemicals public sector and administration technology and telecom faq clientele recent viewed reports why ken reasearch compare reports to make purchase decision prepaid account to get you valuable discount customized research for business study purchase the section to save on next research testimonials this is with regards to your report on india pvc pipes and fitting market outlook industry outlook to  this is a very well written report and accept my compliments on the same  mohit mittal consultant kpmg advisory services i am pleased to see the very useful and productive information in the reportvery well structured great presentation reflect professionalism in your research studies mustafa masood financial analyst  coldwell banker riyadh while we still are studying and analysing your reports about vietnam  thailand we would like to convey to your research team that they have done a very good job in compiling so much of information together we hope to see more of such well researched reports all the best  keep it up  prashant bhagwatgeneral manager mahindra we would like to appreciate ken research for their great efforts and wonderful support in providing the market intelligence report for itpc the information statistics and research are well understandable and very clear to the point we are happy with ken research for their good client service ontime delivery of the report and as said the report itself thank you ken research for bringing the valuable output for us we would be looking forward to have more research with you in the near future wish you a success in your business jestin mathew indonesian trade promotion center the report was very interesting and useful for me marketing manager western union business solutions caladrius biosciences incproduct pipeline review products id  gmdhccdb  pages   july   region global  global markets direct  market research report   request for sample report use kencb kencb  avail a discount of  and cash back of  on all publications applicable on all licenses not applicable on ken research publications limited time period offer tc apply tc apply • promo code can be used  time per user • cash back will be credited with in  hours of the transaction into users ken wallet in case of any issues please contact querykenresearchcom • we reserve the right to cancel any or all offers at our discretion without any aforementioned notice • the money would remain in ken wallet and can be used to purchase any other publication available on the companys website • discount and cashback code will not be applicable on section purchase  previous  next summary scope list of figure list of table licence rights products executive summary caladrius biosciences incproduct pipeline review summary global markets directs caladrius biosciences incproduct pipeline review provides an overview of the caladrius biosciences incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by caladrius biosciences inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of caladrius biosciences inc the report provides overview of caladrius biosciences inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses caladrius biosciences incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features caladrius biosciences incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate caladrius biosciences incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for caladrius biosciences inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding caladrius biosciences incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope contact us ken research ankur gupta head marketing  communications ankur  kenresearchcom  wwwkenresearchcom table of contents table of contents  list of tables  list of figures  caladrius biosciences inc snapshot  caladrius biosciences inc overview  key information  key facts  caladrius biosciences incresearch and development overview  key therapeutic areas  caladrius biosciences incpipeline review  pipeline products by stage of development  pipeline productsmonotherapy  pipeline productspartnered products  partnered productscombination treatment modalities  caladrius biosciences incpipeline products glance  caladrius biosciences incclinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  caladrius biosciences incearly stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  caladrius biosciences incdrug profiles  clbs  product description  mechanism of action  rd progress  clbs  product description  mechanism of action  rd progress  stem cell therapy for amd and retinitis pigmentosa  product description  mechanism of action  rd progress  caladrius biosciences incpipeline analysis  caladrius biosciences incpipeline products by route of administration  caladrius biosciences incpipeline products by molecule type  caladrius biosciences increcent pipeline updates  caladrius biosciences incdormant projects  caladrius biosciences incdiscontinued pipeline products  discontinued pipeline product profiles  clbs  caladrius biosciences inclocations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures caladrius biosciences incpipeline by indication   caladrius biosciences incpipeline by stage of development   caladrius biosciences incmonotherapy products in pipeline   caladrius biosciences incpipeline by route of administration   caladrius biosciences incpipeline by molecule type   list of tables caladrius biosciences inc  key information  caladrius biosciences inc  key facts  caladrius biosciences incpipeline by indication   caladrius biosciences incpipeline by stage of development   caladrius biosciences incmonotherapy products in pipeline   caladrius biosciences incpartnered products in pipeline   caladrius biosciences incpartnered products combination treatment modalities   caladrius biosciences incphase ii   caladrius biosciences incphase i   caladrius biosciences incpreclinical   caladrius biosciences incdiscovery   caladrius biosciences incpipeline by route of administration   caladrius biosciences incpipeline by molecule type   caladrius biosciences increcent pipeline updates   caladrius biosciences incdormant developmental projects  caladrius biosciences incdiscontinued pipeline products   caladrius biosciences inc  other locations  caladrius biosciences inc  subsidiaries  single user license report can be used by individual purchaser only site license report can be shared by unlimited users within one corporate location eg a regional office corporate user license report can be shared globally by unlimited users within the purchasing corporation eg all employees of a single company to know more information on purchase by section please send a mail to query  kenresearchcom   current rd portfolio of caladrius biosciences inc caladrius biosciences inckey therapeutics caladrius biosciences incpipeline overview and promising molecules caladrius biosciences incnews caladrius biosciences inclatest updates caladrius biosciences incpipeline caladrius biosciences incdiscontinueddormant projects related products in vertical vietnam nutraceuticals market outlook to   rising demand for infant products and probiotic supplements to foster future growth ken research  page   july  read more thailand nutraceuticals market outlook to   rising trust over herbal ingredients with increasing use of ginseng in functional foods to foster future growth ken research  page   july  read more korea nutraceuticals market outlook to   rising trust over herbal ingredients with increasing use of ginseng in functional foods to foster future growth ken research  page   july  read more other reports by publisher serinethreonine protein kinase pim  pim h or proto oncogene pim  or pim or ec pipeline review h  global markets direct  page   may  read more osteonecrosispipeline review h  global markets direct  page   may  read more type  diabetespipeline review h  global markets direct  page   may  read more company home about us services categories news contact us careers rss feeds quick links blog industry reports equity research reports country research reports deal directory publishers upcoming publication latest publications other links discounted reports discount coupons media releases testimonial terms  conditions privacy policy disclaimer faqs site map contact us ken research pvt ltd a tower b spaze i tech business park sohna road sector  nbspnbspnbspnbspnbspgurgaon haryana   india   follow us wish to know more about us download company brochure for further enquiry careers apply for job your resume has been successfully received hr will connect you within  days in case your resume gets shortlisted come on we need you make a start to an incredible career applicant name job function job function market research associate market research analyst seo executive content writer web designer hr specialist total experience year year            months months year              skills email id  notice period current ctc  expected ctc ctcmonthly expected ctcmonthly phone number validation   if validation code does not match please refresh the page   know how we roll our services engage with us query  kenresearchcom thanks for submitting the form please refer to the attached brochure company brochure name email company name select country select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others phone no validation   if validation code does not match please refresh the page thanks for submitting the form the concerned team will respond to your query in the next  hours engage with us name designation email phone no company name company url select country select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others requirements comments validation   if validation code does not match please refresh the page net wrap  store cards  dry fruits  ondemand services  online music  bicycle  personal accessories  herbal products  food kiosks  upstream  bricks and blocks  stamping machine  hookah  fishing  breath fresheners  respiratory  neurology devices  petrochemicals  power tools  reservoir development  petroleum fuels  audio systems  specialty chemicals  polymer materials  process outsourcing  intelligence and analytics  artwork products  processed food  mro services  aerospace products  bone growth stimulators  midstream  baby equipment  rubber  equipments and services  airlines travel  electricity generation and transmission  fuel dispenser  refining  biopsy devices compare my shortlist compare my shortlist  facebook facebook   ？ facebook ？？：？，。english us語한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates caladrius biosciences developing next generation cell therapies about caladrius caladrius biosciences inc is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications the company is investigating its lead product candidate clbs an ex vivo expanded polyclonal t regulatory cell therapy for the treatment of recentonset type  diabetes in a currently enrolling phase  trial newsjuly  caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetesjune  caladrius biosciences joins russell microcap® indexjune  invetech and caladrius biosciences receive  good design award® for design of a counterflow centrifuge device for use in the development of cell therapieseventsjune  th international symposium on stem cell therapy  cardiovascular innovationsjune  th annual ld micro invitationalmay   first quarter financial results sign up to our email list to receive caladrius announcements email address this iframe contains the logic required to handle ajax powered gravity forms technologies  capabilitiest regulatory cell technology cd cell technology bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one